Author

Gregory E. Edelstein

Brigham and Women's HospitalORCID 0009-0008-3415-3167Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:host-pathogen & immune response· 2 Approach:statistical model· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Jonathan Z. LiiD· 3 shared Amy K. BarczakiD· 2 shared Brooke M. Leeman· 2 shared Jacob E. LemieuxiD· 2 shared Jeffrey A. SparksiD· 2 shared Julie BoucauiD· 2 shared Karry Su· 2 shared Mamadou Barry· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

Jonathan Z. LiORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologybioRxivPreprintJun 23, 2026

Post-infection immune response in adults with COVID-19 with and without nirmatrelvir-ritonavir treatment and virologic rebound

Dibya Ghimire, Chloe M. Hasund, John Bianchi Colangeli…·Jacob E. Lemieux

This study examines immune responses in adults with COVID-19 who received or did not receive nirmatrelvir-ritonavir, finding no differences in immune markers between those with and without virologic rebound.

DOI 10.64898/2026.06.22.733737

humanproteomics

𝕏 PostBluesky

ImmunologybioRxivPreprintMay 23, 2025

COVID-19 induces persistent transcriptional changes in adipose tissue that are not associated with Long COVID

Soneida DeLine-Caballero, Kalani Ratnasiri, Richard Chen…·Catherine A. Blish

The paper examines transcriptional changes in adipose tissue from subacute COVID-19 and Long COVID patients, finding no persistent viral RNA but significant transcriptional remodeling in subacute cases and no consistent gene expression differences in Long COVID.

1 citation

humanbulk RNA-seq

𝕏 PostBluesky

ImmunologyJournal of VirologyPeer-reviewedFeb 4, 2025

Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance

Tin Phan, Ruy Miguel Ribeiro, Gregory E. Edelstein…·Alan S. Perelson

The paper models viral rebound after nirmatrelvir-ritonavir treatment, finding that target cell preservation and incomplete viral clearance drive rebound, with extended treatment reducing this risk.

21 citationstop 1%

humanstatistical model

𝕏 PostBluesky